A team of scientists led by Scott Abrams at Roswell Park Comprehensive Cancer Center uncovered a pathway associated with metastases to the lung, a common site for cancer spread. The work, just published in JCI Insight, has potentially significant implications that may point to novel cancer therapies.
ImmunityBio Inc. and NCI are partnering to open a clinical trial to study ImmunityBio’s investigational Tri-Ad5 vaccine combination (Adenovirus 5 CEA/MUC1/brachyury) together with its IL-15 superagonist N-803, an immune-enhancer, for people with Lynch syndrome.
Results of the Investigation of Novel Surgical Imaging for Tumor Excision (INSITE) pivotal trial highlight the safety and effectiveness findings of Lumicell’s pivotal trial of its investigational Lumicell Direct Visualization System to identify residual breast cancer following removal of the primary specimen during initial lumpectomy.
Researchers from Stanford AI Health and One Health, the world’s first translational canine cancer care company, published the results from the largest-ever genomic study of canine cancer which revealed a promising path for enhanced human cancer treatments.
In a translational study from UCLA Jonsson Comprehensive Cancer Center, researchers analyzed genetic changes in the organs of recently deceased patients to understand how metastatic cutaneous melanoma spreads in those who had initially benefited from precision therapies.
A team of University of Florida researchers has developed a promising new CRISPR-powered method for noninvasive blood tests that could help clinicians diagnose cancer at earlier stages.
A study led by researchers at the University of Colorado Boulder, published in the journal Exploration of Medicine, is among the first to assess how cannabis bought over the counter at dispensaries—rather than government-supplied or synthetic varieties—impacts cancer symptoms or chemotherapy side effects.
In a first-in-human clinical trial for patients with relapsed multiple myeloma, led by researchers at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5% overall response rate.
While trying to understand what initiates breast cells to become cancerous, researchers at the Vera Bradley Foundation Center for Breast Cancer Research at Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a new target for breast cancer treatment.
Moderna, Inc. and Merck announced April 16 the first presentation of detailed results from the phase IIb KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV).